β-LACTAMASE PRODUCTION RATIO OF CLINICAL ISOLATES AND CLINICAL EFFECT OF SULBACTAM ·AMPICILLIN (SET·ABPC) IN RESPIRATORY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement8; pp. 204 - 213
• Main Authors: KANEHARA, HISASHI, IKEHATA, TAKASHI, OHYA, NOBUO, HAYASE, MITSURU, YAMAZAKI, MICHIKO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 25.12.1988
• Subjects: B.catarrhalis; β-lactamase
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement8_204

We evaluated clinical isolates (Gram-positive cocci group, 320 strains; Enterobacteriaceae, 160 strains; non-Enterobacteriaceae GNR, 122 strains; Haemophilus sp. and Neisseria sp., 67 strains) in the Central Clinical Laboratory of Kanazawa Medical University Hospital for β-lactarnase production and drug susceptibility. The penicillinase production ratio of Staphylococcus aureus was 58.1% and all these strains were resistant to ABPC. However, the ABPC-resistance rate of penicillinase non-producers was 18.4%. The penicillinase production rates of Branharnella sp. and Moraxella sp. were 45.5% and 16.7%, respectively. We therefore consider SBT·ABPC a useful drug for the microbiolggical eradication of S.aureus, Branhamella sp. and Moraxella sp. To evaluate the clinical efficacy of SBT·ABPC, this drug was administered to 19 patients with 20 episodes of respiratory tract infection. The clinical efficacy of SBT·ABPC, except in mycoplasmal pneumonia, was excellent in 2 episodes, good in 11, fair in 5 and poor in 1, the overall efficacy rate being 68.4%. In 6 episodes (fair 5, poor 1) the patients were over 70 years old except for 1 patient, who had severe underlying diseases and complications. The causative organisms were isolated in 16 episodes. The bacterial eradication rate was 87.5%. No severe side effects or abnormalities in clinical laboratory values were found. We consider SBT·ABPC to be a useful antimicrobial agent for the treatment of respiratory tract infections.